Influence of combinations of acetylsalicylic acid, acetaminophen, and diclofenac on platelet aggregation

European Journal of Pharmacology

Volumn 595, Issue 1-3, 2008, Pages 65-68

  Galliard Grigioni, Katja S ^a   Fehr, Martin ^a   Reinhart, Walter H ^a  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Acetaminophen; Aspirin; Diclofenac; NSAID; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; INCUBATION TIME; MALE; NORMAL HUMAN; PORE CLOSURE TIME; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION;

ACETAMINOPHEN; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DICLOFENAC; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 52249123468     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.07.036     Document Type: Article

References (28)

1. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., and Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 35 (2004) 175-178
2. Antithrombotic Trialist's Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
3. Blaicher A.M., Landsteiner H.T., Zweringa J., Leitgeb U., Volf I., and Hoerauf K. Effect of non-selective, non-steroidal anti-inflammatory drugs and cyclo-oxygenase-2 selective inhibitors on the PFA-100 closure time. Anaesthesia 59 (2004) 1100-1103
4. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343 (2000) 1520-1528
5. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddel R., Mortin D., Lnas A., Konstam M.A., Baron J.A., and Adenomatous Polyp Prevention on Vioxx (APROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352 (2005) 1092-1102
6. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tournier B., Vyas S.N., and FitzGerald G.A. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N. Engl. J. Med. 345 (2001) 1809-1817
7. Chan A.T., Manson JoAE., Albert C.M., Chae C.U., Rexrode K.M., Curhan G.C., Rimm E.B., Willett W.C., and Fuchs C.S. Nonsteroidal anti-inflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
8. Francis J., Francis D., Larson L., Helms E., and Garcia M. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice?. Platelets 10 (1999) 132-136
9. Hippisley-Cox J., and Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330 (2005) 1366
10. Hobikoglu G.F., Norgaz T., Aksu H., Ozer O., Erturk M., Destegul E., Akyuz U., Unal, Dai S., and Narin A. The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy. Can. J. Cardiol. 23 (2007) 201-206
11. Kearney P.M., Baigent C., Godwin J., Halls H., Emberson J.R., and Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
12. Kurth T., Glynn R.J., Walker A.M., Chan K.A., Buring J.E., Hennekens C.H., and Gaziano J.M. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal anti-inflammatory drugs. Circulation 108 (2003) 1191-1195
13. Lages B., and Weiss H.J. Inhibition of human platelet function in vitro and ex vivo by acetaminophen. Thromb. Res. 53 (1989) 603-613
14. Livio M., Del Maschio A., Cerletti C., and de Gaetano G. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23 (1982) 787-796
15. 2 synthase cyclooxygenase active site. Biochemistry 35 (1996) 7330-7340
16. MacDonald T.M., and Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 361 (2003) 573-574
17. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitions of cyclooxygenase 2. JAMA 296 (2006) 1633-1644
18. Mitchell J.A., Lucas R., Vojnovic I., Hasan K., Pepper J.R., and Warner T.D. Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J. 20 (2006) 2468-2475
19. Munsterhjelm E., Niemi T.T., Syrjälä M.T., Ylikorkala O., and Rosenberg P.H. Propacetamol augments inhibition of platelet function by diclofenac in volunteers. Br. J. Anaesth. 91 (2003) 357-362
20. Munsterhjelm E., Niemi T.T., Ylikorkala O., Silvanto M., and Rosenberg P.H. Characterization of inhibition of platelet function by paracetamol and its interaction with diclofenac in vitro. Acta Anaesthesiol. Scand. 49 (2005) 840-846
21. Munsterhjelm E., Niemi T.T., Ylikorkala O., Neuvonen P.J., and Rosenberg P.H. Influence on platelet aggregation of i.v. parecoxib and acetaminophen in healthy volunteers. Br. J. Anaesth. 97 (2006) 226-231
22. Pamukcu B., Oflaz H., Oncul A., Umman B., Mercanoglu F., Ozcan M., Meric M., and Nisanci Y. The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J. Thromb. Thrombolysis 22 (2006) 103-110
23. Patrono C., Coller B., FitzGerald G.A., Hirsch J., and Roth G. Platelet-active drugs: the relationship among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 234S-264S
24. Quellet M., and Percival M.D. Mechanism of acetaminophen inhibition of cyclooxygenase isoforms. Arch. Biochem. Biophys. 387 (2001) 273-280
25. Rao G.H., Reddy K.R., and White J.G. Effect of acetaminophen and salicylate on aspirin-induced inhibition of human platelet cyclo-oxygenase. Prostaglandins Leukot. Med. 9 (1982) 109-115
26. Rao G.H.R., Johnson G.G., Reddy K.R., and White J.G. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3 (1983) 383-388
27. Sciulli M.G., Seta F., Tacconelli S., Capone M.L., Ricciotti E., Pistritto G., and Patrignani P. Effects of acetaminophen on constitutive and inducible prostanoid biosynthesis in human blood cells. Br. J. Pharmacol. 138 (2003) 634-641
28. Wuillemin W.A., Gasser K.M., Zeerleder S.S., and Lämmle B. Evaluation of a Platelet Function Analyzer in patients with a bleeding tendency. Swiss Med. Wkly. 132 (2002) 443-448